To study the combined effect of Emblica officinalis (amla) and Curcuma longa (Haldi)on blood sugar level in type 2 Diabetes Mellitus.
Not Applicable
- Conditions
- Health Condition 1: null- patients suffering from type 2 diabets mellietus, on oral hypoglycemic agents.
- Registration Number
- CTRI/2014/06/004686
- Lead Sponsor
- Dr Mrs VAPandit
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Open to Recruitment
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
Patients satisfying all the following criteria would be included in the study:
1. Ready to abide by trial procedures and to give informed consent.
2. Either sex above 40 yrs
3. Type 2 diabetes mellitus for < 5 yrs on Metformin < 1000mg/day and/or Glimepiride < 3mg/day
4. Fasting blood glucose between 126- 234 mg % and post-prandial blood glucose (after a standard meal) between 162mg% to 360mg%
5. HbA1c between 7.0-9.5 %.
Exclusion Criteria
Patients suffering from any of the following conditions will be excluded from the study:
a. Type 1 diabetes mellitus
b. Patients with psychiatric disorder.
c. Patients with H/o hematological disorders
d. Complications of diabetes
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To determine the effect of addition of Nishamalaki in patients of type II DM on oral hypoglycemic (OHA) agents on <br/ ><br>1) Blood sugar level <br/ ><br>2) HbA1c <br/ ><br>Timepoint: 0-3months
- Secondary Outcome Measures
Name Time Method To determine the effect of addition of Nishamalaki in patients of type II DM on oral hypoglycemic (OHA) agents on <br/ ><br>1) Adverse reactions <br/ ><br>2) Changes in the doses of OHAs <br/ ><br>Timepoint: 0-3months